Barclays raised the firm’s price target on Definitive Healthcare to $11 from $10 and keeps an Equal Weight rating on the shares. The company’s billings were down year-over-year in Q4 but saw improving net dollar retention towards the end of the quarter, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DH:
- Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023
- Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
- Definitive Healthcare downgraded to Hold from Buy at Needham
- Definitive Healthcare price target lowered to $11 from $12 at Stifel
- Definitive Healthcare price target lowered to $9 from $10 at Canaccord
